The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. Maria Jose Soler, MD, PhD
Maria José Soler combines her work as an attending nephrologist in the Nephrology Service of Vall d'Hebron Hospital with also an active role in clinical research and Principal Investigator (PI) and Co – Chair of the Experimental Nephrology Group. She is the elected editor-in-chief for CKJ. She graduated in Medicine from the University of Barcelona in 1996 and got her specialization in nephrology in 2002. She has two master’s degrees in Kidney Transplantation (Open University of Catalonia, 2003) and in Hospital and Health Services Management (University of Barcelona, 2019). In 2007, she defended her doctoral thesis on experimental diabetic nephropathy and diabetic nephropathy due to Angiotensin-2 and Angiotensin- 2 converting enzyme, for which she received an extraordinary award.
Peter Rossing
Steno Diabetes Center, University of Copenhagen, Copenhagen, Denmark
Prof. Peter Rossing, MD, DMSc
Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes. Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.
Ofri Mosenzon
Professor of Internal Medicine, Endocrinology and Epidemiology, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
Dr. Ofri Mosenzon, MD, MSc
Ofri Mosenzon is a professor of Internal medicine and Endocrinology in the faculty of Medicine, Hebrew university of Jerusalem, Israel. She is also the manager of the Diabetes Clinical Research Center at the Hadassah Medical Center, Jerusalem, Israel. Prof. Mosenzon received her medical degree from the Faculty of Medicine, Technion, Haifa, Israel. She is board-certified in Internal Medicine and Endocrinology and has an MSc in Clinical Epidemiology from the Hebrew University of Jerusalem. Prof. Mosenzon’s research interests include, but are not limited to, cardiovascular and renal outcomes trials with glucagon-like peptide-1 receptor analogues, and sodium-glucose co-transporter 2 inhibitors. She has led many peer-reviewed publications, and lecture extensively worldwide.
Hiddo Lambers Heerspink
University Medical Center Groningen, Groningen, Netherlands
Prof. Hiddo L. Heerspink, PhD
Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen and visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and received his PhD from the University Medical Center Groningen. Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with chronic kidney disease with a specific focus on personalized medicine. He leads numerous clinical trials with new interventions to reduce kidney and cardiovascular complications of chronic kidney disease. His main expertise includes clinical trial design, personalized medicine as well as methodological aspects and statistical analyses of clinical trials